HaematologyDr. Sukriti GuptaSickle Cell Disease

Senior Consultant, BMT, Haematology & Paediatric Haemato-Oncology, Artemis Hospitals, Gurugram

Part 4 of 11 in Diagnosis and Management of Sickle Cell Disease

Stroke Risk and Screening in Sickle Cell Disease

November 9, 2025

Stroke is one of the most serious complications of sickle cell disease, caused by compromised blood flow to the brain, and it can present with abnormal movements, loss of consciousness or weakness, and can be fatal if not managed promptly. The middle and posterior cerebral artery territories are affected most often, similar to the pattern seen in adult stroke generally.

Transcranial Doppler as the key screening tool

Transcranial Doppler ultrasound measures blood flow velocity in the cerebral vessels and identifies which sickle cell patients are at higher risk of stroke before it happens. The first scan is recommended at two years of age; if the flow pattern is abnormal, follow-up scans move to every two to three months, and if it is normal, screening can continue at intervals of six months to a year.

Why regular monitoring matters

Regular follow-up with a general practitioner or paediatrician, every two to three months even in the absence of symptoms, is the practical foundation that makes this kind of stroke screening effective. Picking up an abnormal Doppler pattern early allows preventive medication and closer monitoring to begin before a stroke occurs, rather than only reacting after one has already happened.

This article is based on a Jivo Masterclass session conducted by Dr. Sukriti Gupta, Senior Consultant, BMT, Haematology and Paediatric Haemato-Oncology, Artemis Hospitals, Gurugram. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording

Looking for a haematology consultation or a second opinion? Get in touch with the Jivo team

This guide is based on a live Jivo Masterclass — Dr. Sukriti Gupta taught doctors across Africa on November 9, 2025.

FROM THE LIVE Q&A

DR

Dr. Brian (Zambia)

What is your comment on the use of hydroxyurea in pregnancy, and what are the alternative options?

SG

Dr. Sukriti Gupta

In pregnant women who have generally done well and had infrequent pain crises up to childbearing age, hydroxyurea is usually held during pregnancy since it is not a good option for fetal development. Good hydration and avoiding any other stressful conditions are advised instead, and folic acid supplementation must continue.

See all 9 questions from this masterclass →

Book a Consultation with Dr. Sukriti Gupta

Book on WhatsApp

Or message us on WhatsApp: +91 98182 98669

Frequently Asked Questions

At what age do we commence hydroxyurea?

As early as the disease is detected, sometimes as young as two months of age.

What is the upper age limit for bone marrow transplant, and what are the cost implications for full match versus half match donors?

The best outcomes are under 16 years, 16 to 25 is still viable, and beyond 25 the risks rise and require much more detailed pre-transplant workup, including cardiac and kidney function assessment, though age is not always a fixed barrier if organ function is well preserved and the family is fully committed. A full-match sibling transplant typically costs around $24,000 to $25,000, rising for older patients closer to adult body weight, while a half-match or unrelated-donor transplant through a registry costs around $33,000 to $34,000, since registry and donor-related costs are higher even though complications are reduced.

In terms of treatment, how is gene therapy done, and is it possible for all patients?

Gene therapy uses the patient's own stem cells rather than a donor, mobilised and collected the same way as for a transplant, then modified in a laboratory using either a viral vector for gene addition or CRISPR-Cas9 editing to correct the underlying genetic change, a process that currently takes around six months. Because the cells being returned are the patient's own, recovery is generally faster than with a donor transplant, but the therapy currently has FDA approval only for patients aged 12 and older, and it remains expensive and not yet widely available outside the US, Europe and a handful of other countries.

In developing countries where finances are a barrier for most families, would you recommend gene therapy or bone marrow transplant?

If finances are genuinely not a barrier, gene therapy is worth choosing once it is better established, since it avoids the donor-related risks. But where finances are a limiting factor, an experienced allogeneic bone marrow transplant programme should still be trusted: it has decades of mature outcome data behind it, and families should not exhaust all their resources chasing a gene therapy process that could stall partway through. If a patient is having an acute crisis such as a recent stroke, there is also often not enough time to wait the six to eight months gene therapy currently requires, and transplant should be pursued instead.

Are biological parents automatically half-match donors, and what are the realistic chances of finding a match within the immediate family?

Parents are usually a half match by default, provided they are not sicklers themselves and have no disqualifying condition such as HIV or organ damage. A full-match sibling occurs in about 25% of cases, and a half-matched sibling is actually a better donor than a half-matched parent, since sibling cells are better tolerated with fewer pre-existing antibody reactions. Beyond parents and siblings, more distant relatives such as aunts, uncles or cousins are rarely even a half match, so realistic donor availability is mostly limited to the immediate family.

What is the main tool used to screen for stroke risk in sickle cell disease?

Transcranial Doppler ultrasound, which measures blood flow velocity in the cerebral vessels. The first scan is recommended at two years of age, with follow-up frequency depending on whether the result is normal or abnormal.

Which parts of the brain are most commonly affected by stroke in sickle cell disease?

The middle and posterior cerebral artery territories are affected most often, though the anterior territory can occasionally be involved as well.

Need Expert Medical Guidance?

Connect with leading specialists through the Jivo Healthcare network for personalized advice.

Get Expert Opinion